Linda Coe, R.N., M.S.N
Acting Director–Associate Director for Management and Operations
Peter Jahrling, Ph.D.
Peter N. Jahrling, Ph.D., has served since 2005 as the director and chief scientist of the Integrated Research Facility (IRF) in Frederick, Maryland. From the ground floor up, he has been instrumental in designing and building maximum biosafety level-4 and animal biosafety level-4 laboratories. He has enacted his vision of developing imaging services that are not currently available at other maximum containment laboratories. By applying his experience across the spectrum of the research pipeline, he speeds the discovery and delivery of interventions targeting high consequence viral pathogens. In this role, he oversees preclinical research programs with an emphasis on applying translational medicine to improve clinical outcomes. In outbreaks of emerging pathogens, viral agents are identified, isolated, and characterized in order to rapidly respond to these outbreaks.
Dr. Jahrling also serves as chief of the Emerging Viral Pathogens Section (EVPS) that is co-located at the IRF and at the National Institutes of Health (NIH) Bethesda, Maryland, campus. EVPS conducts basic research to elucidate the pathophysiological processes associated with viral hemorrhagic fevers and other Category A pathogens. Generic solutions to broad classes of microbial agents should emerge from an understanding of disease processes. Thus, EVPS assesses a broad spectrum of diseases, including newly discovered pathogens, for commonalities amenable to generic intervention strategies.
Dr. Jahrling received his Ph.D. in medical microbiology from Cornell Medical College. After serving as an Army officer at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), he was eventually appointed scientific advisor for the institute. He advised the commander on the development and coordination of research programs directed at prevention, treatment, and surveillance of biowarfare viral disease threats. He was the principal scientist responsible for diagnostic techniques and medical countermeasure development for these viruses.
Dr. Jarhling has authored or co-authored more than 160 scientific publications. He is a subject matter expert and consultant to numerous agencies including the National Institutes of Health, National Academy of Sciences, World Health Organization (WHO), U.S. Department of State, National Security Council, U.S. Department of Health and Human Services, and Centers for Disease Control and Prevention. He was head of the WHO Collaborating Center for Arbovirus and Hemorrhagic Fever Reference and Research at USAMRIID. Since 1996, Dr. Jahrling has served as a consultant to the National Academy of Sciences/Institute of Medicine’s Russian/U.S. Collaborative Program for Research and Monitoring of Pathogens of Global Importance. His awards and honors include the Secretary of Defense Medal for Meritorious Civilian Service; the Federal Career Service Outstanding Professional Award; the Department of the Army Achievement Medal for Civilian Service; the Order of Military Medical Merit; the Joel M. Dalrymple Award for Distinguished Medical Service (awarded by the Association of Military Surgeons of the United States) and the Lifetime Achievement Award for Excellence in Filovirus Research.
Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, Fabozzi G, Nichol ST, Ksiazek TG, Rollin PE, Wahl-Jensen V, Bailey M, Jahrling PB, Roederer M, Koup RA, Sullivan NJ.Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog. 2010 May 20;6(5):e1000904.
Kuhn JH, Jahrling PB. Clarification and guidance on the proper usage of virus and virus species names. Arch Virol. 2010 Apr;155(4):445-53.
Alkhalil A, Strand S, Mucker E, Huggins JW, Jahrling PB, Ibrahim SM. Inhibition of monkeypox virus replication by RNA interference.Virol J. 2009 Nov 4;6:188.
LeDuc JW, Anderson K, Bloom ME, Carrion R Jr, Feldmann H, Fitch JP, Geisbert JB, Geisbert TW, Holbrook MR, Jahrling PB, Ksiazek TG. Potential impact of a 2-person security rule on BioSafety Level 4 laboratory workers. Emerg Infect Dis. 2009 Jul;15(7):e1.
Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, Paragas J, Matthias L, Smith MA, Jones SM, Hensley LE, Feldmann H, Jahrling PB. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008 Nov;4(11):e1000225.
Le Duc JW, Anderson K, Bloom ME, Estep JE, Feldmann H, Geisbert JB, Geisbert TW, Hensley L, Holbrook M, Jahrling PB, Ksiazek TG, Korch G, Patterson J, Skvorak JP, Weingartl H. Framework for leadership and training of Biosafety Level 4 laboratory workers.Emerg Infect Dis. 2008 Nov;14(11):1685-8.
Nabel GJ, Sullivan NJ, Geisbert TW, Jahrling PB, inventors; Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, assignee. Method of accelerated vaccination against Ebola viruses. United States patent US 7,635,485. 2009 Dec 22.
Haynes JR, Schmaljohn CS, Fuller DL, Schmaljohn A, Jahrling PB, inventors; PowerJect Vaccines Inc., assignee. Genetic induction of anti-viral immune response and genetic vaccine for filovirus. United States patent US 6,200,959. 2001 Mar 13.
Lisa Hensley, Ph.D., M.S.P.H.
Associate Director of Science
Dr. Hensley is the deputy director of the Integrated Research Facility at the National Interagency Biodefense Campus at Fort Detrick in Frederick, Maryland. She is one of the premier researchers of Ebola and Marburg hemorrhagic fevers, Lassa fever, Middle East respiratory syndrome coronavirus (MERS-CoV), sudden acute respiratory syndrome (SARS), and smallpox, among other agents. Her research has focused on development and characterization of animal models for high-consequence pathogens, as well as the development and testing of candidate countermeasures (drugs, vaccines, anti-sense technologies, and antibody-based products) in these models. She was recently director of the regulatory science medical countermeasures initiative, Food and Drug Administration (FDA), and before that, chief of viral therapeutics, virology division, U. S. Army Medical Research Institute for Infectious Diseases (USAMRIID). She has unique expertise in viral research and regulatory science, with insight into the hurdles and challenges of advanced medical product development. Dr. Hensley is uniquely qualified to direct basic research aims, in addition to the design and completion of additional studies necessary for investigational new drug applications to FDA.
Martinez O, Johnson JC, Honko A, Yen B, Shabman RS, Hensley LE, Olinger GG, Basler CF. Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol. 2013 Apr;87(7):3801-14.
Twenhafel NA, Mattix ME, Johnson JC, Robinson CG, Pratt WD, Cashman KA, Wahl-Jensen V, Terry C, Olinger GG, Hensley LE, Honko AN. Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques. Vet Pathol. 2013 May;50(3):514-29.
Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A, Yen JY, Geisbert J, Paragas J, Fritz E, Olinger G, Young HA, Rubins KH, Karp CL. Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis. 2013 Jul 15;208(2):310-8.
Olinger, GG, Pettitta J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, and Zeitlin L. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18030-5.
Gire SK, Stremlau M, Andersen KG, Schaffner SF, Bjornson Z, Rubins K, Hensley L, McCormick JB, Lande ES, Garry RF, Happi C, Sabeti PC. Epidemiology. Emerging disease or diagnosis? Science. 2012 Nov 9;338(6108):750-2.
Friedrich B, Trefry J, Biggins J, Hensley L, Honko A, Smith D, Olinger G. Potential vaccines and post-exposure treatments for filovirus infections. Viruses. 2012 Sep;4(9):1619-50.